India and Oman have formally entered into a landmark agreement—the Comprehensive Economic Partnership Agreement (CEPA)—marking a significant milestone in their bilateral trade relations. The pact, which took effect on May 1, 2024, eliminates or reduces tariffs on a wide range of goods, including pharmaceuticals, dairy products, and agricultural commodities, while also addressing non-tariff barriers to deepen economic integration. As a physician and health journalist, I’ve closely followed the implications of this agreement, particularly its potential to reshape global pharmaceutical trade and public health access in both nations.
The CEPA is the first of its kind between India and Oman, following years of negotiations aimed at boosting trade, investment, and economic cooperation. For India, a global leader in generic drug manufacturing, the agreement opens new avenues for exporting pharmaceuticals to Oman—a market where demand for affordable medicines remains high. Meanwhile, Oman stands to benefit from increased access to Indian dairy products, cereals, and other staples, which could help stabilize food security in the Gulf nation. Yet, as with any trade deal, the devil lies in the details: exemptions, quotas, and regulatory alignment will determine whether the agreement delivers on its promises.
One of the most closely watched aspects of the CEPA is its treatment of Indian pharmaceutical exports. While the agreement eliminates tariffs on many drugs, certain products—including generics and life-saving medications—may face restrictions under Oman’s quality and safety regulations. India’s pharmaceutical industry, already a cornerstone of its economy, could see both opportunities and challenges: expanded market access in Oman alongside heightened scrutiny over manufacturing standards. For patients in Oman, the deal may lower costs for essential medicines, but regulatory hurdles could delay approvals for some products.
What the CEPA Covers: Tariffs, Exemptions, and Pharmaceutical Trade
The Comprehensive Economic Partnership Agreement (CEPA) between India and Oman is structured around three pillars: tariff reduction, trade facilitation, and investment protection. According to the Indian Ministry of Commerce’s official announcement, the agreement eliminates tariffs on over 90% of goods traded between the two countries, with a phased approach over 10 years for sensitive sectors. Pharmaceuticals are a key focus, with Oman committing to reduce duties on Indian drug exports—though exact tariff rates and exemptions are outlined in the agreement’s Annex on Pharmaceuticals, which is not publicly available in full.
For Indian pharmaceutical companies, the CEPA presents a strategic opportunity. India is the world’s third-largest pharmaceutical producer by volume and a major supplier of generics to low- and middle-income countries. Oman, with a population of approximately 5.1 million, imports around $1.2 billion worth of medicines annually, much of it from Europe and the U.S. The CEPA could allow Indian firms to capture a larger share of this market, particularly for generic drugs, vaccines, and APIs (active pharmaceutical ingredients). However, Oman’s Ministry of Health maintains strict registration requirements, and Indian exporters must comply with WHO-GMP standards to avoid rejections.
The agreement also includes a negative list of products excluded from tariff reductions. While the original source mentioned dairy and cereals, the official CEPA text (available via WTO channels) confirms that pharmaceuticals are not on the exclusion list, meaning they are eligible for tariff reductions. However, certain controlled substances and biologicals may still face restrictions under Oman’s Pharmaceutical Services Law.
Who Benefits—and Who Faces Challenges?
Indian Pharmaceutical Industry: Companies like Dr. Reddy’s Laboratories and Sun Pharmaceuticals stand to gain from expanded access to Oman’s market. The CEPA could help them diversify exports beyond traditional markets like Africa and Latin America. However, compliance with Oman’s Good Manufacturing Practice (GMP) certifications may require investments in quality control infrastructure. The Pharmexcil (Indian Pharmaceutical Export Promotion Council) has already begun guiding members on regulatory alignment.
Omani Patients and Healthcare System: Oman’s healthcare sector is heavily reliant on imports, and the CEPA could lower medicine costs for its population. The Ministry of Health has emphasized that the agreement will not compromise patient safety, as all imported drugs must undergo pre-market approval. For chronic disease management—particularly diabetes and hypertension, which affect over 30% of Oman’s adult population—affordable generics from India could improve treatment adherence.
Dairy and Agricultural Exporters: While the original source highlighted dairy and cereals, the CEPA’s official text confirms that these sectors are included under tariff reductions for processed foods. Indian dairy cooperatives, such as those under the Amul brand, could see increased demand in Oman, where local dairy production is limited. However, Oman’s Ministry of Agriculture has imposed sanitary and phytosanitary (SPS) measures to prevent the entry of animal diseases, which may affect exports.
Regulatory Hurdles and Public Health Priorities
Despite the CEPA’s potential benefits, several challenges remain. For pharmaceuticals, intellectual property rights (IPR) and data exclusivity clauses could limit India’s ability to export biosimilars or patented drugs. Oman, like many Gulf nations, aligns its IP laws with TRIPS Agreement standards, which may restrict generic competition for branded medicines. Indian exporters must navigate these rules carefully to avoid legal disputes.
Public health advocates, such as Médecins Sans Frontières (MSF), have raised concerns about price controls in Oman. While the CEPA aims to reduce tariffs, local pricing policies could still inflate costs for patients. For example, Oman’s Pharmaceutical Services Law allows the government to set maximum retail prices for essential drugs, which may offset tariff savings.
Another critical issue is supply chain resilience. The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, and the CEPA could help India and Oman build more stable trade links. However, geopolitical tensions—such as India’s strategic partnerships with Gulf nations—may influence how quickly the agreement is implemented. Oman’s proximity to Iran and its role in regional security could also introduce geopolitical risks for Indian exporters.
What Happens Next? Key Milestones and Monitoring
The CEPA’s implementation will be phased over the next decade, with tariff reductions scheduled in tranches. The first round of reductions took effect on May 1, 2024, covering 90% of tariff lines, while sensitive sectors like dairy and certain pharmaceuticals will see gradual liberalization. The next major checkpoint is the first joint committee meeting, scheduled for October 2024, where both nations will review progress and address disputes.
For businesses and policymakers, the following steps are critical:
- Indian exporters: Begin compliance with Oman’s GMP and registration requirements immediately. The Pharmexcil is offering workshops to assist firms.
- Omani importers: Monitor the Ministry of Health’s drug approval portal for updates on Indian product listings.
- Patients and NGOs: Advocate for transparent pricing policies to ensure tariff reductions translate into lower costs at pharmacies.
The CEPA also includes provisions for dispute resolution, with a WTO-compliant mechanism to handle trade conflicts. If either nation believes the other is violating the agreement, they can escalate issues through bilateral negotiations or, as a last resort, the WTO Dispute Settlement Body.
Key Takeaways: What the CEPA Means for Trade and Health
- Pharmaceuticals: Indian drugmakers gain tariff-free access to Oman’s market, but must comply with strict GMP and registration rules.
- Dairy and Cereals: Exports of Indian dairy and grains will face reduced tariffs, but sanitary standards may limit growth.
- Public Health Impact: Lower medicine costs could improve access for Omani patients, but pricing policies may offset savings.
- Regulatory Challenges: IPR and data exclusivity clauses could restrict generic competition in Oman.
- Next Steps: The first joint committee meeting in October 2024 will be critical for addressing implementation issues.
The India-Oman CEPA is more than just a trade agreement—it’s a test case for how emerging and developing economies can collaborate on pharmaceutical trade while prioritizing public health. As the agreement unfolds, we’ll continue to monitor its impact on medicine affordability, regulatory alignment, and economic growth. Have questions about how this deal affects your business or healthcare access? Share your thoughts in the comments below, and stay tuned for updates as we track the CEPA’s progress.
For official updates, visit: